Despite these limitations, our findings suggest a realistic scenario of a prospective clinical trial in pancreatic cancer patients with the combination therapy of PARP inhibitor and anti-PD-L1/PD-1. The gene discussed is PARP1; the disease is pancreatic neoplasm.